Le Lézard
Classified in: Health
Subjects: LAW, PSF

Johnson & Johnson Hit with $750M Punitive Damages Verdict for Failing to Warn about Cancer-Causing Asbestos in Talc Products


NEW BRUNSWICK, N.J., Feb. 7, 2020 /PRNewswire/ -- A New Jersey jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $750 million in punitive damages to four cancer victims who charged that the company's iconic Johnson's Baby Powder contained cancer-causing asbestos.

In assessing the punitive damages on Thursday, the jury agreed that J&J had acted "maliciously or in wanton disregard" of the safety risks of the four plaintiffs. In addition to the size of the damages, the verdict is significant because it occurred just blocks away from J&J's headquarters, said trial lawyer Chris Panatier of Dallas-based Simon Greenstone Panatier, who represented the plaintiffs, along with Moshe Maimon of Levy Konigsberg in New York and Chris Placitella of Cohen, Placitella, & Roth in New Jersey.

"This case is really about the fact that J&J structured their last 50 years of conduct around concealing that there were, and have always been, asbestos fibers in their baby powder," Mr. Panatier said. "They designed test methods that they knew lacked the sensitivity to detect the asbestos that was present and then on the occasions when asbestos was found, took steps to make excuses, blame non-existent contamination, delete and alter test results. The jury saw all of that."

It was also the first time J&J CEO Alex Gorsky has taken the stand in a talc case. Under questioning from Mr. Panatier, Gorsky admitted that he had not made an effort to go through the actual relevant documents before going on national television to proclaim the safety of talc three days after a Reuters story alleging that J&J knew of and concealed the fact of asbestos in the product.

In September, a separate jury found Johnson & Johnson liable in the lawsuit by plaintiffs Douglas Barden, David Etheridge, D'Angela McNeill and Will Ronning and awarded $37.3 million in actual damages. That verdict set the stage for a separate trial to determine punitive damages.

The case is Barden, et al. v. Johnson & Johnson, et al. in the Superior Court of New Jersey Law Division, Middlesex County, Docket No.: MID-L-1809-17 AS.

Following the verdict, the judge who presided over the trial indicated that the award would be reduced to $186.5 million based on state law caps that limit punitive damages to five times the compensatory amount.

This is Simon Greenstone Panatier's most recent win against Johnson & Johnson. In May 2018, attorneys David Greenstone and Mr. Panatier won a $25.75 million verdict after a California jury found manufacturing and design defects in Johnson's Baby Powder due to the presence of asbestos. Shortly after the compensatory verdict in Barden, David Greenstone obtained a $40 million verdict in Los Angeles in Cabibi v. Johnson & Johnson, et al. The firm has earned numerous other verdicts on behalf of individuals in litigation related to talc-based products.

Simon Greenstone Panatier, P.C., is a nationally recognized trial law firm with a reputation for creative and aggressive representation of clients in a wide variety of catastrophic personal injury matters nationwide. For more information, visit http://www.sgptrial.com/.

Media Contact:
Mark Annick
800-559-4534
[email protected] 

 

SOURCE Simon Greenstone Panatier, P.C.


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: